EXECUTIVE ENGAGEMENTS
POOL
10862
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1303
Interactions with Platform & by Email
PARTICIPANTS
326
Unique # Participated
VALIDATIONS
82
Responses Validated*
COMPANIES
47
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
138
PAGES
215
EDITION
18
PRICE
USD 5450
CODE
MCP-6736
*Engagement stats are ongoing and dynamic
Sign-in with email to View Deeper Validated Engagement Details -
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Companion Diagnostics estimated at US$3.4 Billion in the year 2020, is projected to reach a revised size of US$9.2 Billion by 2027, growing at aCAGR of 15.1% over the period 2020-2027. Assay kits & Reagents, one of the segments analyzed in the report, is projected to record 14.3% CAGR and reach US$6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software & Services segment is readjusted to a revised 16.8% CAGR for the next 7-year period.
The Companion Diagnostics market in the U.S. is estimated at US$1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 14.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.5% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.
SELECT PLAYERS
Abbott Molecular; Agilent Technologies, Inc.; bioMérieux SA; Cepheid; Danaher Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine Inc.; Laboratory Corporation of America® Holdings; Leica Biosystems Nussloch GmbH; Merck & Co. Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories, Inc.; QIAGEN N.V.; Quest Diagnostics Inc.; Thermo Fischer Scientific Inc.
SEGMENTS
» Product & Service (Assay kits & Reagents, Software & Services) » Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), Other Technologies) » Indication (Oncology, Neurology, Other Indications) » End-Use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Companion Diagnostics: An Introductory Prelude |
| Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development |
| Broader Scope and Applications Rev Up Growth Opportunities |
| Healthy Growth Projected over the Next Few Years |
| Developed Regions: Key Revenue Contributors |
| Market Witnesses Fast Paced Growth in Developing Regions |
| Northbound Trajectory in R&D Spending Creates Conducive Environment |
| Prevailing Economic Scenario Favors Funding Pattern |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Growing Significance of Personalized Medicine Remains a Major Market Driver |
| Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum |
| Herceptin Lays the Road for Companion Diagnostics |
| Oncology - Dominant Therapy Area for CDx |
| Rising Incidence of Cancer Propels the Need for CDx Tests |
| Technology Advancements to Widen CDx Use Case |
| PCR: Dominant Technology Type for CDx Testing |
| Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing |
| Significant Role of Biomarkers in Companion Diagnostics |
| Critical Healthcare Needs of Aging Population Underpin CDx Sales |
| Regulatory Scenario Favors CDx Market |
| Resolving Prevailing Challenges: Critical for Future Growth of CDx Market |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Assay kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Assay kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Polymerase Chain Reaction (PCR) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Polymerase Chain Reaction (PCR) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Immunohistochemistry (IHC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Immunohistochemistry (IHC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| USA Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| USA Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| USA Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| China Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| China Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| China Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| France Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| France Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| France Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| UK Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| UK Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| UK Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 47 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com